ATP11B gene silencing restored the sensitivity of ovarian cancer cell lines to cisplatin, as well as in mice bearing ovarian tumors derived from cisplatin-sensitive and resistant cells. This evidence concerns the gene ATP11B and ovarian carcinoma.